Aclaris Therapeutics (ACRS) Assets Average (2017 - 2025)
Historic Assets Average for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $182.3 million.
- Aclaris Therapeutics' Assets Average rose 617.7% to $182.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.3 million, marking a year-over-year increase of 617.7%. This contributed to the annual value of $208.9 million for FY2024, which is 758.16% down from last year.
- Aclaris Therapeutics' Assets Average amounted to $182.3 million in Q3 2025, which was up 617.7% from $193.6 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Assets Average registered a high of $275.8 million during Q3 2021, and its lowest value of $116.1 million during Q1 2021.
- Moreover, its 5-year median value for Assets Average was $224.7 million (2021), whereas its average is $216.9 million.
- Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 26072.56% in 2021, then tumbled by 2798.26% in 2024.
- Aclaris Therapeutics' Assets Average (Quarter) stood at $257.4 million in 2021, then increased by 1.46% to $261.1 million in 2022, then decreased by 20.39% to $207.9 million in 2023, then dropped by 3.14% to $201.4 million in 2024, then fell by 9.45% to $182.3 million in 2025.
- Its Assets Average stands at $182.3 million for Q3 2025, versus $193.6 million for Q2 2025 and $209.2 million for Q1 2025.